Valitor to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
12 Agosto 2024 - 3:05PM
Valitor, a biotechnology company engineering better medicines to
conquer drug limitations, today announced that president and chief
scientific officer Wesley Jackson, Ph.D., will present a company
overview describing Valitor’s platform technology and pipeline at
the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on
Thursday, August 15, 2024 at 7:00 a.m. ET. In addition, Dr. Jackson
will discuss Valitor’s cutting-edge approach in ophthalmology as a
speaker on an Age Related Macular Degeneration (AMD) panel
available on-demand to registered attendees.
To access the live webcast or subsequent archived recording of
the presentation, please visit the Events section of the Valitor
website, located after the News section at
https://www.valitorbio.com/#news.
About ValitorValitor is conquering limitations
of established drug targets by leveraging its multivalent
biopolymer technology to maximize benefits for patients. The
company is initially focused on developing long-acting molecules
aimed at capturing several large markets in ophthalmology.
Valitor’s lead product is a long-acting inhibitor of VEGF designed
to reliably extend the duration of a single dose in humans to six
months or more, which would offer a substantial benefit for the
majority of patients that require dosing approximately every three
months with the current market leaders. Valitor’s proprietary
platform technology has been shown in preclinical models to safely
enable intravitreal treatment with unprecedented target tissue
durability and potency. For more information on the company, please
visit its website at https://www.valitorbio.com/ or follow its
LinkedIn page.
Investor Contact Alexandra Santos
asantos@wheelhouselsa.com
Media ContactAljanae
Reynoldsareynolds@wheelhouselsa.com
Valitor Contactinfo@valitorbio.com